Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-alpha therapy during pregnancy: three-center study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10193779" target="_blank" >RIV/00216208:11110/13:10193779 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/13:10193779
Result on the web
<a href="http://dx.doi.org/10.3109/00365521.2013.812141" target="_blank" >http://dx.doi.org/10.3109/00365521.2013.812141</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3109/00365521.2013.812141" target="_blank" >10.3109/00365521.2013.812141</a>
Alternative languages
Result language
angličtina
Original language name
Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-alpha therapy during pregnancy: three-center study
Original language description
Objective. Substantial number of women with inflammatory bowel disease (IBD) conceives while on anti-TNF-alpha therapy. The aim was to assess the safety and efficacy of anti-TNF-alpha treatment during pregnancy and to analyze relationship of neonatal andmaternal anti-TNF-alpha levels at delivery with gestational age at the last exposure. Material and methods. Women with IBD exposed to anti-TNF-alpha therapy during pregnancy were included. Data on anti-TNF-alpha treatment, disease activity, concomitantmedication, pregnancy and newborn outcome were recorded. Anti-TNF-alpha levels from cord blood were assessed by ELISA. Results. Forty-one pregnancies (27 Crohn's disease; 14 ulcerative colitis) were exposed to infliximab (IFX; 32) and adalimumab (ADA; 9). Ten (24%) women had active disease at conception and 31 (76%) were in remission with 3 patients experiencing relapse during pregnancy. Anti-TNF-alpha therapy started prior to and after conception in 32 and 9 women, respectively. There w
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EC - Immunology
OECD FORD branch
—
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Scandinavian Journal of Gastroenterology
ISSN
0036-5521
e-ISSN
—
Volume of the periodical
48
Issue of the periodical within the volume
8
Country of publishing house
GB - UNITED KINGDOM
Number of pages
8
Pages from-to
951-958
UT code for WoS article
000322850500008
EID of the result in the Scopus database
—